...
首页> 外文期刊>Gynécologie, obstétrique, fertilité & sénologie. >Comparing prediction performances of F-18-FDG PET and CGFL/Curie nomogram to predict pathologic complete response after neoadjuvant chemotherapy for HER2-positive breast cancers
【24h】

Comparing prediction performances of F-18-FDG PET and CGFL/Curie nomogram to predict pathologic complete response after neoadjuvant chemotherapy for HER2-positive breast cancers

机译:比较预测性能F-18-FDG宠物和CGFL /居里诺模图预测病理新辅助化疗后完全缓解为her2阳性乳腺癌

获取原文
获取原文并翻译 | 示例
           

摘要

abstract_textpObjectives. - The aim of this study was to compare the value of F-18-fluorodesoxyglucose positron emission tomography (F-18-FDG PET/CT) with CGFL/Curie nomogram to predict a pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) in women with human epidermal growth factor 2 (HER2)-positive breast cancer treated by trastuzumab./ppMethods. - Fifty-one women with HER2-positive breast cancer treated with trastuzumab plus taxanebased NAC were retrospectively included from January 2005 to December 2015. For F-18-FDG PET/CT, the analyzed predictor was the maximum standardized uptake value of the primary tumor and axillary nodes after the first course of NAC (PET2.SUVmax). pCR was defined by no residual infiltrative tumor but in situ tumor was accepted. Accuracy of CGFL/Curie nomogram and PET2 .SUVmax was evaluated measuring sensitivity (Se), specificity (Sp), positive predictive value (PPV) and negative predictive value (NPV). Combined prediction was evaluated testing predictor's associations./ppResults. - For CGFL/Curie nomogram's performances, Se, Sp, PPV and NPV were respectively: 76% (95%Cl: 58-90%), 57% (95%Cl: 43-66%), 55% (95%Cl: 42-65), 77% (95%Cl: 59-90%). For PET2.SUVmax 's performances, Se, Sp, PPV and NPV were respectively: 67% (95%Cl: 48-81%), 77% (95%Cl: 64-97%), 67% (95%Cl: 48-82%), 77% (95%Cl: 64-87%). ROC curves for these predictors were similar; the areas under the curve were 0.6 (95%Cl: 0.56-0.64) for PET2 .SUVmax and 0.55 (95%Cl: 0.50-0.59) for CGFL/Curie nomogram. Combined prediction was efficient with Se at 80%, VPN at 76%, Sp at 78% and VPP at 81%./ppConclusions. - CGFL/Curie nomogram and PET2.SUVmax were two efficient predictors of pCR in patients with HER2-positive breast cancer. Combined prediction has an improved accuracy. (C) 2020 Elsevier Masson SAS. All rights reserved./p/abstract_text
机译:& abstract_text & p目标。本研究的目的是比较的价值F-18-fluorodesoxyglucose正电子发射断层扫描(F-18-FDG PET / CT) CGFL /居里诺模图预测病理完成新辅助化疗后的反应(pCR)(NAC)的女性人类表皮生长因子2 (HER2)阳性乳腺癌的治疗曲妥珠单抗。;/ p & p方法。51 her2阳性乳腺癌的女性曲妥珠单抗治疗+ taxanebased南汽回顾性包括从2005年1月2015年12月。分析预测是最大的标准化原发肿瘤的吸收值和腋窝节点在南京的第一道菜(PET2.SUVmax)。但原位肿瘤是渗透性的肿瘤接受。PET2 .SUVmax评估测量灵敏度(Se)、特异性(Sp),阳性预测值(PPV)以及阴性预测值(NPV)。组合预测是评估测试预测的协会。你们;/ p & p结果。CGFL /居里列线图的表演、Se、Sp, PPV率和净现值分别为:76% (95% cl: 58 - 90%),57% (95% cl: 43 - 66%), 55% (95% cl: 42 - 65), 77%(95% cl: 59 - 90%)。Se、Sp、PPV和NPV分别为:67%(95% cl: 48 - 81%), 77% (95% cl: 64 - 97%), 67% (95% cl:48 - 82%), 77% (95% cl: 64 - 87%)。这些预测是相似的;曲线0.6 PET2 (95% cl: 0.56 - -0.64).SUVmax和0.55 (95% cl: 0.50 - -0.59)CGFL /居里列线图。高效和Se为80%,VPN为76%,Sp在78%和VPP 81%。;/ p & p结论。CGFL /居里列线图和PET2。pCR患者的有效预测因子her2阳性乳腺癌。有一个改进的准确性。马森SAS。保留。;/ p & / abstract_text

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号